Sintilimab combined with AVD for the treatment of composite Hodgkin lymphoma and follicular lymphoma: a case report and literature review.
Composite lymphoma has been rarely reported due to its low incidence.
APA
Ye H, Huang L, et al. (2025). Sintilimab combined with AVD for the treatment of composite Hodgkin lymphoma and follicular lymphoma: a case report and literature review.. Frontiers in oncology, 15, 1692954. https://doi.org/10.3389/fonc.2025.1692954
MLA
Ye H, et al.. "Sintilimab combined with AVD for the treatment of composite Hodgkin lymphoma and follicular lymphoma: a case report and literature review.." Frontiers in oncology, vol. 15, 2025, pp. 1692954.
PMID
41602412
Abstract
Composite lymphoma has been rarely reported due to its low incidence. The treatment of composite lymphoma depends on the specific lymphoma subtypes involved. No standardized therapeutic regimen has been established. We tried to treat the patient with Sintilimab+AVD for composite Hodgkin lymphoma and follicular lymphoma, after which the patient was able to maintain a normal quality of life and achieved partial remission (PR). To the best of our knowledge, this is the first attempt to use the PD-1 inhibitor combined with the AVD regimen successfully for the treatment of composite Hodgkin lymphoma and follicular lymphoma.
같은 제1저자의 인용 많은 논문 (5)
- Clinical Efficacy of 830 nm LED Photobiomodulation Therapy on Postoperative Blepharoplasty Complications.
- Artificial intelligence-based tumor-stroma ratio quantification reveals prognostic value and stromal-driven immunosuppression in colorectal cancer: an international validation study.
- Construction and validation of a predictive model for hypothermia complication during endoscopic thyroidectomy for thyroid cancer.
- Structural and functional insights into targeting hTERT G-quadruplex by levo-Tetrahydropalmatine in the non-small cell lung cancer.
- Bidirectional Mendelian Randomization and Multi-Omics Uncover Causal Serum Metabolites and Neuro-Related Mechanistic Pathways in Acute Myeloid Leukemia.